pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells
- PMID: 35945679
- PMCID: PMC9804328
- DOI: 10.1111/his.14768
pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells
Abstract
Aims: Pleomorphic xanthoastrocytoma (PXA) is a rare circumscribed glioma, characterized by frequent BRAF p. V600E mutation, and classified as grade 2 or 3. Owing to overlapping clinical-pathological features, the histological distinction from glioblastoma (GBM) with giant cells (GCs) is challenging. Based on the high frequency of TP53 and RB1 alterations in the latter, this study aimed to assess the value of BRAF, p53, and pRB immunostainings in the differential diagnosis.
Methods and results: In 37 GBMs with ≥30% GCs and in eight PXAs, we assessed the alterations of 409 cancer-related genes and immunostainings for BRAF, p53, and pRB. GBMs with GCs were TP53-mutated in 30 cases, RB1-altered in 11, and BRAF-mutated in none. PXAs were BRAF-mutated in six cases, TP53-mutated in three, and RB1-altered in none. pRb immunostaining was lost in 25 GBMs (11 RB1-altered and 14 RB1-unaltered), retained in all PXAs and six GBMs, and inconclusive in six GBMs. pRb loss had 100% specificity and 80.6% sensitivity for GBM with GCs. P53 immunostaining was observed in 22 TP53-mutated GBMs and in one TP53-mutated PXA. It showed 87.5% specificity and 60% sensitivity to identify GBM with GCs. BRAF immunostaining corresponded to BRAF mutation status and it had 100% specificity and 75% sensitivity for detecting PXA.
Conclusion: This study shows for the first time that loss of pRB immunostaining is sensitive and specific for distinguishing GBM with GCs from PXA in routine practice. Thus, it could complement an immunohistochemical panel that includes BRAF and p53 immunostainings for the differential diagnosis.
Keywords: RB1; giant cell; glioblastoma; pRB; pleomorphic xanthoastrocytoma.
© 2022 The Authors. Histopathology published by John Wiley & Sons Ltd.
Conflict of interest statement
None to declare.
Figures


Similar articles
-
Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.Neuropathology. 2018 Jun;38(3):218-227. doi: 10.1111/neup.12459. Epub 2018 Mar 13. Neuropathology. 2018. PMID: 29532523
-
BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.Brain Pathol. 2014 Apr;24(3):221-9. doi: 10.1111/bpa.12111. Epub 2014 Jan 29. Brain Pathol. 2014. PMID: 24345274 Free PMC article.
-
Epithelioid GBMs show a high percentage of BRAF V600E mutation.Am J Surg Pathol. 2013 May;37(5):685-98. doi: 10.1097/PAS.0b013e31827f9c5e. Am J Surg Pathol. 2013. PMID: 23552385 Free PMC article.
-
Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.Clin Neurol Neurosurg. 2022 Oct;221:107379. doi: 10.1016/j.clineuro.2022.107379. Epub 2022 Jul 21. Clin Neurol Neurosurg. 2022. PMID: 35932588 Review.
-
Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.World Neurosurg. 2022 Aug;164:e922-e928. doi: 10.1016/j.wneu.2022.05.066. Epub 2022 May 23. World Neurosurg. 2022. PMID: 35618235 Review.
References
-
- Giannini C, Capper D, Figarella‐Branger D et al. Pleomorphic xanthoastrocytoma. In Brat DJ, Ellison DW, Figarella‐Branger D et al. eds. WHO classification of tumours editorial board. Central nervous system tumours. Lyon: International Agency for Research on Cancer, 2021.
-
- Rodrigues A, Bhambhvani H, Medress ZA, Malhotra S, Hayden‐Gephart M. Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas. J. Neurooncol. 2021; 153; 321–330. - PubMed
-
- Louis DN, Aldape KD, Capper D et al. Glioblastoma, idh‐wildtype. In Brat DJ, Ellison DW, Figarella‐Branger D et al. eds. Who classification of tumours editorial board. Central nervous system tumours. Lyon: International Agency for Research on Cancer, 2021.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous